
Casey R Tak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2971024/publications.pdf Version: 2024-02-01



CASEV D TAK

#	Article	IF	CITATIONS
1	North Carolina Pharmacists' Support for Hormonal Contraception Prescription Status Change. Journal of Pharmacy Practice, 2023, 36, 769-776.	1.0	0
2	Pharmacistâ€administered audiology screening for pediatric cystic fibrosis patients exposed to highâ€dose aminoglycosides: A pilot study. Pediatric Pulmonology, 2022, 57, 1814-1817.	2.0	0
3	Perinatal Substance Use Care Coordination: The Need for One Care Plan. North Carolina Medical Journal, 2022, 83, 231-231.	0.2	2
4	Cancer surveillance for patients with Li-Fraumeni Syndrome in Brazil: A cost-effectiveness analysis. The Lancet Regional Health Americas, 2022, 12, 100265.	2.6	1
5	Telemedicine Services During COVIDâ€19: Considerations for Medically Underserved Populations. Journal of Rural Health, 2021, 37, 231-234.	2.9	47
6	Improving access to care through Advanced Practice Registered Nurses: Focus on perinatal patients with Opioid Use Disorder. Journal of Advanced Nursing, 2021, 77, 4-10.	3.3	5
7	BRCA testing and outcomes in women with breast cancer. Breast Cancer Research and Treatment, 2021, 186, 839-850.	2.5	5
8	Development and validation of a predictive model to predict and manage drug shortages. American Journal of Health-System Pharmacy, 2021, 78, 1309-1316.	1.0	7
9	Self-reported vs RUCA rural-urban classification among North Carolina pharmacists. Pharmacy Practice, 2021, 19, 2406.	1.5	6
10	The essential role of pharmacists facilitating vaccination in older adults: the case of Herpes Zoster. Human Vaccines and Immunotherapeutics, 2020, 16, 70-75.	3.3	14
11	Poison-related visits in a pediatric emergency department: A retrospective analysis of patients who bypass poison control centers. American Journal of Emergency Medicine, 2020, 38, 1554-1559.	1.6	2
12	Contraceptive prescribing: Professional standards and legal protections for the pharmacist. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 293-294.	1.5	1
13	Lifetime Prevalence and Correlates of Patient-Perceived Medical Errors Experienced in the U.S. Ambulatory Setting: A Population-Based Study. Health Equity, 2020, 4, 430-437.	1.9	4
14	Exploration of the STOP Act and Opioid Deaths in North Carolina, 2010–2018. American Journal of Public Health, 2020, 110, 1573-1577.	2.7	6
15	Role of Pharmacists in Hormonal Contraceptive Access: A Survey of North Carolina Pharmacists. Pharmacy (Basel, Switzerland), 2020, 8, 191.	1.6	5
16	Unintentional Pediatric Poisoning Exposures in an Emergency Department. Pediatric Emergency Care, 2020, Publish Ahead of Print, .	0.9	1
17	A Modeling Exercise to Identify Predictors of Student Readiness for Advanced Pharmacy Practice Experiences. American Journal of Pharmaceutical Education, 2020, 84, 7783.	2.1	18
18	The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency. Journal of the American Board of Family Medicine, 2020, 33, 998-1003.	1.5	2

CASEY R TAK

#	Article	IF	CITATIONS
19	Patient Satisfaction With Venous Thromboembolism Treatment. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961986466.	1.7	2
20	Consumer awareness and utilization of clinical services, and their satisfaction and loyalty with community pharmacies: Analysis of a US nationwide survey. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 335-342.	1.0	6
21	Payers' Perspectives on Pharmacist-Directed Care in a Community Pharmacy Setting. Annals of Pharmacotherapy, 2019, 53, 916-921.	1.9	7
22	Pharmacist-prescribed hormonal contraception: A review of the current landscape. Journal of the American Pharmacists Association: JAPhA, 2019, 59, 633-641.	1.5	15
23	Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60+. Journal of Pharmacy Technology, 2019, 35, 258-269.	1.0	1
24	Understanding Factors Associated with Quality of Life in Patients with Venous Thromboembolism. Thrombosis and Haemostasis, 2019, 119, 1869-1876.	3.4	12
25	Effect of a central call center on employee perceptions of safety culture within community pharmacies in an academic health system. American Journal of Health-System Pharmacy, 2019, 76, 360-365.	1.0	1
26	Costâ€effectiveness of early cancer surveillance for patients with Li–Fraumeni syndrome. Pediatric Blood and Cancer, 2019, 66, e27629.	1.5	20
27	The effect of a prescription order requirement for pharmacist-administered vaccination on herpes zoster vaccination rates. Vaccine, 2019, 37, 631-636.	3.8	6
28	Modeling Doctor of Pharmacy Students' Stress, Satisfaction, and Professionalism Over Time. American Journal of Pharmaceutical Education, 2019, 83, 7432.	2.1	9
29	Impact of Pharmacist Previsit Input to Providers on Chronic Opioid Prescribing Safety. Journal of the American Board of Family Medicine, 2018, 31, 105-112.	1.5	30
30	Cost-effectiveness of emergency contraception options over 1 year. American Journal of Obstetrics and Gynecology, 2018, 218, 508.e1-508.e9.	1.3	9
31	The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. European Journal of Clinical Pharmacology, 2017, 73, 1055-1069.	1.9	19
32	The value of a poison control center in preventing unnecessary ED visits and hospital charges: A multi-year analysis. American Journal of Emergency Medicine, 2017, 35, 438-443.	1.6	18
33	Factors predicting self-reported medication low adherence in a large sample of adults in the US general population: a cross-sectional study. BMJ Open, 2017, 7, e014435.	1.9	21
34	Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics. International Journal of Adolescent Medicine and Health, 2017, 29, .	1.3	0
35	Assessment and use of drug information references in Utah pharmacies. Pharmacy Practice, 2017, 15, 839-839.	1.5	13
36	Pregnancyâ€induced changes in the pharmacokinetics of caffeine and its metabolites. Journal of Clinical Pharmacology, 2016, 56, 590-596.	2.0	45

#	Article	IF	CITATIONS
37	Special population considerations and regulatory affairs for clinical research. Clinical Research and Regulatory Affairs, 2015, 32, 45-54.	2.1	35